Related Experiment Video
Updated: Nov 23, 2025
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Simultaneous blocking of the pan-RAF and S100B pathways as a synergistic therapeutic strategy against malignant
Ke-Jia Wu1, Shih-Hsin Ho2, Chun Wu3
1State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China.
Abstract:
Melanoma is a very aggressive form of skin cancer. Although BRAF inhibitors have been utilized for melanoma therapy, advanced melanoma patients still face a low five-year survival rate. Recent studies have shown that CRAF can compensate for BRAF depletion via regulating DNA synthesis to remain melanoma proliferation. Hence, targeting CRAF either alone or in combination with other protein pathways is a potential avenue for melanoma therapy. Based on our previously reported CRAF-selective inhibitor for renal cancer therapy, we have herein discovered an analogue (complex 1) from the reported CRAF library suppresses melanoma cell proliferation and melanoma tumour growth in murine models of melanoma via blocking the S100B and RAF pathways. Intriguingly, we discovered that inhibiting BRAF together with S100B exerts a novel synergistic effect to significantly restore p53 transcription activity and inhibit melanoma cell proliferation, whereas blocking BRAF together with CRAF only had an additive effect. We envision that blocking the pan-RAF and S100B/p53 pathways might be a novel synergistic strategy for melanoma therapy and that complex 1 is a potential inhibitor against melanoma via blocking the pan-RAF and S100B pathways.
Insights
A novel CRAF inhibitor, complex 1, effectively suppresses melanoma growth by targeting S100B and RAF pathways. Combining BRAF and S100B inhibition shows synergistic effects, offering a potential new melanoma therapy strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Melanoma remains aggressive with poor survival rates despite BRAF inhibitors.
- CRAF compensates for BRAF depletion, driving melanoma proliferation.
- Targeting CRAF presents a potential therapeutic strategy for melanoma.
Purpose of the Study:
- To investigate a novel CRAF inhibitor (complex 1) for melanoma therapy.
- To explore the therapeutic potential of targeting CRAF, S100B, and BRAF pathways in melanoma.
- To evaluate the synergistic effects of combined BRAF and S100B inhibition.
Main Methods:
- Screening a CRAF inhibitor library to identify a novel analogue (complex 1).
- Assessing complex 1's efficacy in suppressing melanoma cell proliferation and tumor growth in murine models.
- Investigating the effects of inhibiting BRAF, CRAF, and S100B, individually and in combination, on melanoma cell proliferation and p53 activity.
Main Results:
- Complex 1 suppressed melanoma cell proliferation and tumor growth by inhibiting S100B and RAF pathways.
- Inhibiting BRAF and S100B together demonstrated a synergistic effect, restoring p53 transcription and inhibiting proliferation.
- Combined BRAF and CRAF inhibition showed only an additive effect on melanoma proliferation.
Conclusions:
- Complex 1 is a potential melanoma inhibitor targeting pan-RAF and S100B pathways.
- Blocking pan-RAF and S100B/p53 pathways represents a novel synergistic strategy for melanoma treatment.
- Combined BRAF and S100B inhibition offers a promising therapeutic approach for advanced melanoma.
More Related Videos
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
06:09Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...